Erythrocyte Patents (Class 435/7.25)
-
Patent number: 6623983Abstract: Apparatus and methods are disclosed which facilitate immobilization of magnetically labelled particulate entities, e.g., cells, preferably in a defined pattern, on a collection surface via binding between specific binding pair members, as an aid to particle analysis.Type: GrantFiled: September 23, 1999Date of Patent: September 23, 2003Assignee: Immunivest CorporationInventors: Leon W. M. M. Terstappen, Galla C. Rao
-
Publication number: 20030170143Abstract: The invention discloses a test device comprising a substrate suitably adapted so as to provide aperture(s) wherein said aperture(s) are suitably adapted so as to support selected supportive material (3) so that fluid samples can be efficiently dispensed onto said supportive material (3) located within said apertures. Furthermore, said supportive material is further adapted so as to provide suitable guide means for checking the adequacy of the sample collected. Subsequently said test device can be placed in a suitable pouch (12) or the like, wherein said pouch (12) is adapted so as to provide desiccant properties (13) and thus to dry a fluid sample more efficiently. Eventually said test device is presented to an automated analyser for processing or the like, alternatively, said test device may be adapted so as to provide on the spot results. The device can said test device may be adapted so as to provide on the spot results.Type: ApplicationFiled: August 10, 1999Publication date: September 11, 2003Inventor: ROBERT WILLIAM CUNNINGHAM
-
Patent number: 6607723Abstract: Antibody-mediated xenograft rejection is attenuated by (1) removing preformed antibodies to various identified carbohydrate xenoantigens from the recipient's circulation prior to transplantation by extracorporeal perfusion of the recipient's blood over a biocompatible solid support to which the xenoantigens are bound and/or (2) parenterally administering a xenoantibody-inhibiting amount of an identified xenoantigen to the recipient shortly before graft revascularization and thereafter.Type: GrantFiled: June 2, 1995Date of Patent: August 19, 2003Assignees: Alberta Research Council, Integris Baptist Medical Center, Inc.Inventors: A. Heather Good, David K.C. Cooper, Andrew J. Malcolm
-
Patent number: 6586200Abstract: The present invention relates to a method for detecting substances specifically inhibiting a type III secretion mechanism and functions of the type III secretory proteins, within short time and large amounts thereof, without depending upon animal infectious experiments. Namely it relates to the method for detection of a type III secretory mechanism inhibitor comprising mixing a bacterium having the type III secretory mechanism and an erythrocyte suspension, adding the type III secretory mechanism inhibitor thereto, and detecting changes in the thus formed hemolytic activity. The method for detecting substances can be treated large amount of samples within short time by exhibiting the substances inhibiting the type III secretion mechanism or the functions of the type III secretory proteins as numerical index of the hemolytic activity of erythrocytes. Consequently, the present invention is useful for development of drugs.Type: GrantFiled: May 21, 2002Date of Patent: July 1, 2003Assignee: The Kitasato InstituteInventors: Satoshi Omura, Akio Abe
-
Patent number: 6537766Abstract: Specific Ikaros mutations, as well as the correlation of the presence of the specific Ikaros mutations and other wild-type non-DNA binding Ikaros isoforms with lymphoid cell abnormality is provided in the in the invention. Methods for detecting and treating lymphoid cell abnormality, including hematoloic malignancy, are also provided.Type: GrantFiled: November 5, 1999Date of Patent: March 25, 2003Assignee: Hughes InstituteInventors: Fatih M. Uckun, Mya L. Crotty
-
Patent number: 6537760Abstract: In a competitive receptor binding assay for detecting TSH-receptor auto-antibodies in a biological sample, the sample is reacted in a reaction mixture which contains (i) a TSH-receptor or TSH-receptor preparation; (ii) a primary competitor, for example labelled TSH; and (iii) an agent for separating a complex composed of the TSH-receptor and the elements bound thereto of the reaction mixture from the liquid phase. According to the invention, the reaction is carried out in the presence of at least one monoclonal or polyclonal antibody specific against a partial peptide sequence of the TSH eceptor. This specific antibody is used to immobilize a complex of TSH-receptor and primary competitor and/or as secondary competitor for another part of the TSH-receptor auto-antibodies expected in a sample. The primary or secondary competitors are or can be selectively labelled.Type: GrantFiled: August 4, 1999Date of Patent: March 25, 2003Assignee: B.R.A.H.M.S. AktiengesellschaftInventors: Andreas Bergmann, Joachim Struck
-
Patent number: 6531323Abstract: An agglutination assay method for quantitatively determination of an analyte in a liquid sample using particles bearing an anti-analyte. A non-fluid substance which retains the particles while suppressing the diffusion of the particles therein is used as a medium which is to be a place where the agglutination of the particles takes place. Upon analysis, a solation agent is added to the non-fluid substance medium to increase the fluidity of the non-fluid substance, thereby the particles bearing the anti-analyte can diffuse in the medium to cause the agglutination with the analyte. Preferably, the solation agent is added to the non-fluid medium together with the sample. The non-fluid substance medium containing the particle-labeled anti-analyte can be stored with a higher stability in the dry state. A dry analysis element for enabling such analysis method is also provided.Type: GrantFiled: January 28, 2000Date of Patent: March 11, 2003Assignee: Fuji Photo Film Co., Ltd.Inventors: Hiroshi Shinoki, Yoshikazu Amano
-
Patent number: 6514714Abstract: The present invention provides an improved method for detection of panel reactive antibodies in serum of a subject against HLA class I antigens, which comprises the steps of adding serum from a subject to an array of microbeads, each microbead presenting HLA antigens from a cell population presenting the same HLA antigens; incubating the serum and microbeads for sufficient time for anti-HLA antibodies in the serum to bind to the HLA antigens presented on the microbeads; removing the serum components which do not specifically bind with the HLA antigens presented on the microbeads; incubating the microbeads with a labeled ligand capable of specifically binding with anti-HLA antibodies bound to said HLA antigens; removing the labeled ligand which is not bound to said HLA antigens; and detecting the presence of labeled ligand bound to said HLA antigens by flow cytometry.Type: GrantFiled: April 17, 2000Date of Patent: February 4, 2003Assignee: One LambdaInventors: Jar-How Lee, Rui Pei
-
Patent number: 6482598Abstract: The subject invention pertains to antibodies that have binding specificity for an antigen that is expressed on a subset of human, hematopoietic mononuclear cells, including a hematopoietic stem cell population, but is not expressed on normal, mature myeloid cells. In one embodiment, a monoclonal antibody, MG1, is provided. This antibody is useful in methods of isolating cell suspensions from human blood and marrow that can be employed in bone marrow transplantation, genetic therapy, and in treating other diseases of the hematopoietic system. Cell suspensions containing MG1+ human hematopoietic cells are also provided, as well as therapeutic methods employing the cell suspensions. The subject invention also pertains to the novel antigen recognized by the subject antibodies.Type: GrantFiled: June 4, 2001Date of Patent: November 19, 2002Assignee: Morphogenesis, Inc.Inventors: Michael J. P. Lawman, Patricia Lawman
-
Patent number: 6475749Abstract: Rh antibody hybrids for use in testing red blood cells for the presence of one or more Rh factors. The Rh hybrid antibody may also be used in therapeutic procedures which require the use of Rh antisera. The hybrid antibody includes an IgG anti-Rh antibody which has a polymeric tailpiece attached to the carboxy terminal end of each of the IgG antibody heavy chains. A hemagglutinin method is provided for Rh phenotyping in which agglutination of Rh-positive red blood cells is achieved in a one-step process involving addition of the hybrid Rh antisera to the red blood cells being tested.Type: GrantFiled: August 11, 1999Date of Patent: November 5, 2002Assignee: The Regents of the University of CaliforniaInventors: Sherie L. Morrison, Ramon Montaño
-
Patent number: 6465259Abstract: A method for quantitatively and/or qualitatively assaying an analyte in a sample, wherein the analyte is a receptor binding compound, has low detection limits equivalent to those of radioreceptor assays. The method comprises the steps of a) contacting the sample with material comprising a receptor for the analyte in order for receptor-analyte binding to occur and b) further contacting the sample with a detectable ligand for the receptor in order for receptor-ligand binding to occur, followed by c) separating the resulting receptor bound and free fractions, d) subjecting the receptor bound fraction to dissociating conditions releasing the ligand from the receptor and e) assaying for the dissociated ligand in a manner known per se for the detection of the detectable ligand.Type: GrantFiled: May 6, 1999Date of Patent: October 15, 2002Assignee: Merska B.V.Inventors: Maria Johanna Janssen, Kornelis Ensing, Rokus Arie De Zeeuw
-
Patent number: 6413716Abstract: A method for detection of human parvovirus B19, comprising the steps of: (1) bringing a sample into contact with fixed P-antigen positive red cells in a medium at pH 5.6±0.6; and (2) determining whether or not hemagglutination occurs; and a reagent for detecting human parvovirus B19, wherein the reagent comprises fixed P-antigen positive red cells.Type: GrantFiled: June 18, 1996Date of Patent: July 2, 2002Assignee: The Japanese Red Cross SocietyInventors: Fumihiro Takakura, Hiroyuki Sato, Yoshiaki Maeda
-
Patent number: 6413727Abstract: A human gene termed APC is disclosed. Methods and kits are provided for assessing mutations of the APC gene in human tissues and body samples. APC mutations are found in familial adenomatous polyposis patients as well as in sporadic colorectal cancer patients. APC is expressed in most normal tissues. These results suggest that APC is a tumor suppressor.Type: GrantFiled: May 25, 1995Date of Patent: July 2, 2002Assignees: The Johns Hopkins University, University of Utah, Japanese Foundation for Cancer Research Cancer Institute, Zeneca LimitedInventors: Hans Albertsen, Rakesh Anand, Mary Carlson, Joanna Groden, Philip John Hedge, Geoff Joslyn, Kenneth Kinzler, Alexander Fred Markham, Yusuke Nakamura, Andrew Thliveris, Bert Vogelstein, Raymond L. White
-
Patent number: 6410696Abstract: A method of measuring the amount of cyclosporin in a sample suspected of containing cyclosporin is disclosed. A method of inactivating interfering cross-reactive material in an assay for measuring the amount of cyclosporin in a sample suspected of containing cyclosporin is also disclosed. Compositions wherein cyclosporin is conjugated to an immunogenic carrier or a label, optionally through a linking group, at an alanine nitrogen atom of the cyclic backbone of cyclosporin are also disclosed. Compositions wherein atiocyclosporin is conjugated, optionally through a linking group, to an immunogenic carrier or a label are also disclosed. Where cyclosporin is conjugated to an immunogenic carrier, the conjugates may be used as immunogens for the preparation of antibodies which are capable of recognizing cyclosporin.Type: GrantFiled: November 13, 2000Date of Patent: June 25, 2002Assignee: Dade Behring Marburg GmbHInventors: Dariush Davalian, Maureen H. Beresini, Svetlana Alexander, Mae Wan-Leng Hu, Edwin F. Ullman
-
Publication number: 20020072129Abstract: A container having a flexible wall receives a continuous flow of a biological fluid that includes a target antigen and emits a continuous flow of the biological fluid at least partially depleted from the target antigen. The container further comprises a compartment with magnetic beads coupled to an affinity marker that binds the target antigen, and the target antigen is separated from the biological fluid using a magnetic force and an automatic mechanical force, wherein at least one of the magnetic force and automatic mechanical force is transmitted through the flexible wall.Type: ApplicationFiled: October 11, 2001Publication date: June 13, 2002Inventors: Michael Poirier, Vijay K. Mahant
-
Patent number: 6387622Abstract: Ligand-aminodextran-(phycobiliprotein or tandem dye) conjugates useful for detection of a desired target biological material by providing an enhanced fluorescent signal are described. Also described is a method for a single-measurement quantification of multiple populations of cells based upon the labeling of different pairs of cell populations, each pair containing mutually exclusive cell receptors which are expressed at substantially similar receptor densities with labeled ligands for each receptor. One cell population is labeled with a ligand capable of binding to a first cell surface receptor which ligand is directly conjugated to a fluorescent phycobiliprotein or tandem dye; and a second cell population is labeled with a ligand capable of binding to a second cell surface receptor, which ligand is cross-linked to an aminodextran to a fluorescent phycobiliprotein or tandem dye.Type: GrantFiled: October 27, 1999Date of Patent: May 14, 2002Assignee: Coulter International Corp.Inventors: Olavi Siiman, Alexander Burshteyn, Ravindra Mylvaganam, Robert Raynor, Patricia Roth, Cecilia Smith, Julie Wilkinson
-
Patent number: 6359119Abstract: The invention relates to novel aminocarboxylate ligands that are suitable for complexing with a radionuclide, and are useful as therapeutic agents and as imaging agents for diagnostic purposes. In accordance with the present invention, a method of preparing a compound of formula fac-[M(CO)3(OH2)3]+ (I) wherein M is Mn, 99mTc, 186Re or 188Re, involves reacting a metal in permetallate form with carbon monoxide and stannous ion. The compound of formula (I) can be reacted with a ligand Lx to form a compound of the formula fac-[M(CO)3Lx]n (II) wherein M is as defined above, Lx is a monodentate or multidentate ligand or a mixture of these ligands, and n is a charge of the ligand Lx increased with one + charge. The invention also is directed to novel compounds, and kits for carrying out the disclosed methods.Type: GrantFiled: May 24, 2000Date of Patent: March 19, 2002Assignee: Mallinckrodt Inc.Inventors: David W. Pipes, Mary E. Dyszlewski, Elizabeth G. Webb
-
Patent number: 6331395Abstract: A method of identifying embryonic or fetal red blood cells in a sample containiing maternal blood cells and embryonic or fetal red blood cells or both, the method comprising determining which cell or cells contain or express an adult liver component. A method of isolating embryonic or fetal red blood cells from a sample containing maternal blood cells and embryonic or fetal red blood cells or both, the method comprising isolating the cells which contain or express an adult liver component. A method of determining a fetal abnormality the method comprising identifying or isolating embryonic or fetal cells according to the above methods and analysing said embryonic or early fetal cells for said abnormality. Use of a means for determining whether a cell contains or expresses an adult liver component for identifying or isolating an embryonic or fetal red blood cell.Type: GrantFiled: September 8, 1999Date of Patent: December 18, 2001Assignee: The University of DundeeInventors: Ann Burchell, Robert Hume
-
Patent number: 6330058Abstract: A method and apparatus for characterizing the type of a blood sample are provided wherein an optical density spectrum of the sample is collected over a predetermined wavelength range. A reference optical density spectrum is collected over a predetermined wavelength range for a portion of the blood sample diluted in saline. Another portion of the blood sample is then mixed with an antibody corresponding to a known blood type (e.g., anti-A, anti-B, anti-D antibody). The optical density spectrum is then collected over a predetermined wavelength range for blood diluted with saline and each antibody in saline. The slopes are then calculated over a predetermined wavelength range for each spectrum. A numerical indicator of agglutination is then calculated by dividing the slope of each antibody-treated sample by the slope of the sample in saline. The resulting number is multiplied by 100.Type: GrantFiled: April 13, 2000Date of Patent: December 11, 2001Assignee: University of South FloridaInventors: Luis Humberto Garcia-Rubio, Smita Narayanan, German Leparc, Robert Potter, Sharyn Orton
-
Patent number: 6309827Abstract: This invention provides for a rapid and convenient method of simultaneous collection of both genomic and diagnostic information from a single sample on a bibulous pad by differential extraction of the diagnostic information from the genomic information. It is a surprising discovery of this invention that a PCR assay on the contents of the bibulous pad provides results comparable in reliability, specificity, and sensitivity to the best available serum (blood) based assays. The assays of this invention can be used to confirm each other, either by detecting the genomic information leading to the diagnostic information, or by detecting in the genomic information, a predisposition to a disease and confirming the presence of the disease through diagnostic testing.Type: GrantFiled: March 27, 1998Date of Patent: October 30, 2001Assignee: OraSure Technologies, Inc.Inventors: Andrew S. Goldstein, Richard K. Bestwick
-
Patent number: 6306615Abstract: This invention relates to monoclonal antibodies that recognize modified &bgr;-tubulin isotypes, methods of using such antibodies to detect modified &bgr;-tubulin isotypes, methods of using such antibodies to monitor &bgr;-tubulin modifying agents administered to a patient, methods of using such antibodies to isolate modified &bgr;-tubulin, and methods of detecting the anti-modified &bgr;-tubulin antibodies.Type: GrantFiled: August 19, 1999Date of Patent: October 23, 2001Assignee: Tularik Inc.Inventors: Holger Beckmann, Edit Santha
-
Patent number: 6303390Abstract: Method and test kit for assaying in a sample an analyte which is a bloodgroup antigen present on erythrocytes or an antibody binding to such a bloodgroup antigen. To that end, the sample is treated with a reagent containing a binding partner for the analyte, so that a complex of bloodgroup antigen present on erythrocytes and antibody bound thereto is formed if the sample contains analyte. The analyte is a bloodgroup antigen present on erythrocytes, the analyte binding partner is an antibody capable of binding to the bloodgroup antigen and if the analyte is an antibody binding to a bloodgroup antigen, the analyte binding partner is the bloodgroup antigen present on erythrocytes. Erythrocytes, complex or non-complexed, are then separated from non-bound antibodies using a separation medium with a density higher than that of the liquid containing the antibodies but lower than the density of crythrocytes.Type: GrantFiled: September 20, 1999Date of Patent: October 16, 2001Assignee: Stichting Sanquin BloedvoorzieningInventors: Pieter Johannes Den Boer, Eric Marinus Maria Van der Donk, Ronald Victor Wilhelmus Van Eijk
-
Patent number: 6291249Abstract: A cell containing sample is separated into a cell containing portion and a substantially cell depleted portion, by mixing the sample with particles to produce a cell containing network, and separating the network from the remaining substantially cell depleted portion within a plurality of confining walls, wherein at least one of the walls is flexible. While in some aspects the separation is performed employing a magnetic force, in other aspects the separation is performed using two forces, wherein one force is a magnetic force and the other force is a mechanical force. It is contemplated that whole blood may be used as the sample, and that the cell-containing portion largely comprises a network of inter-linked red blood cells. It is especially contemplated that separation involves antiligands, preferably primary antibodies that bind to a ligand such as antigen on or in red blood cell membranes, and secondary antibodies that bind to the primary antibodies.Type: GrantFiled: February 28, 2000Date of Patent: September 18, 2001Assignee: Qualigen, Inc.Inventors: Vijay Mahant, Byron Doneen
-
Patent number: 6287791Abstract: This invention relates to an improved method for the multi-parameter analysis of cells from peripheral blood or bone marrow. The method uses a nucleic acid dye, at least two fluorescently labelled monoclonal antibodies and at least two light scatter parameters to differentiate and discriminate between and among different cells in the blood or bone marrow.Type: GrantFiled: May 6, 1994Date of Patent: September 11, 2001Assignee: Becton Dickinson and CompanyInventors: Leon W M M Terstappen, Chia-Huei Chen
-
Patent number: 6274337Abstract: The present invention provides novel microfluidic devices and methods that are useful for performing high-throughput screening assays. In particular, the devices and methods of the invention are useful in screening large numbers of different compounds for their effects on a variety of chemical, and preferably, biochemical systems.Type: GrantFiled: March 19, 1998Date of Patent: August 14, 2001Assignee: Caliper Technologies Corp.Inventors: J. Wallace Parce, Anne R. Kopf-Sill, Luc J. Bousse
-
Patent number: 6255455Abstract: The invention includes Rh(D) binding proteins, including antibodies, and DNA encoding such proteins. Methods of generating such proteins and DNAs are also included.Type: GrantFiled: January 29, 1999Date of Patent: July 3, 2001Assignee: The Trustees of the University of PennsylvaniaInventor: Donald L. Siegel
-
Patent number: 6251611Abstract: A method of determining the presence of chronic volume dependent hypertension is provided wherein a determination is made as to whether there has been a substantial reduction in phosphorylation of the blood-derived protein or renal proximal brush border membrane protein and if such reduction exists concluding that chronic volume dependent hypertension exists in a patient. The method may advantageously be practiced by employing blood serum or blood plasma as the body specimen containing the protein in determining whether a patient has chronic volume dependent hypertension, a cellular component of the blood, such as a blood-derived protein coming from the plasma membrane of lymphocytes. The method may include subsequent therapeutic patient treatment. Related diagnostic apparatus is also provided.Type: GrantFiled: September 26, 1997Date of Patent: June 26, 2001Assignee: Tulane University Medical CenterInventor: Jules B. Puschett
-
Patent number: 6218130Abstract: This invention provides a method of measuring oxidative response of cells without recourse to preparation of cell culture. The process involves: 1) preparing suspensions of cells from a living host in isotonic solutions, 2) preparing samples of test materials in isotonic solution containing tagged choline, 3) adding the cells suspension prepared in step 1 to the samples prepared in step 2, 4) incubating the product of step 3 with shaking for 2-90 minutes, 5) extracting and drying the lipid phase from the product of step 4, and 6) subjecting the product of step 5 to a scintillation counter to measure choline which has been incorporated into phosphatidylcholine (PC). An increase in incorporation of choline into PC in the short term indicates oxidative stress or free radical induced damage. Because the method of the invention using the cell isolates does not require the expense of cell culture with concomitant expense and possibility of cell change, it is particularly useful for clinical evaluation.Type: GrantFiled: September 25, 1998Date of Patent: April 17, 2001Inventor: Robert Lamb
-
Patent number: 6210889Abstract: An enriched fetal cell sample is prepared from maternal blood by first separating a maternal blood sample on a three layer density gradient, and collection of the layer containing the lymphocytes and a layer immediately beneath the lymphocytes which presumably contains the nucleated fetal red blood cells and low density maternal red blood cells. The top layer in the gradient would contain the plasma and lighter components and the bottom layer would contain high density maternal red blood cells. The collected cells are then placed in a hypotonic solution and centrifuged to separate a fetal cell pellet, which contains enriched levels of fetal cells of varying types. The recovered pellet is fixed twice with Carnoy fixative and the fixed cells are then spread on a slide for FISH analysis.Type: GrantFiled: January 27, 1999Date of Patent: April 3, 2001Assignee: The Universite LavalInventors: Regen Drouin, Jean-Claude Forest, Jacques Masse
-
Patent number: 6204002Abstract: The invention provides a compound represented by the following formula (I) wherein m is an integer of 2-15; n is an integer of 0-12; R represents a sugar chain or a derivative thereof; R′ represents a general formula (II) (wherein p is an integer of 0-4, q is an integer of 0-5; r is an integer of 2-5; R12 and R13 are the same or different and each represents a hydrogen atom, a lower alkyl group, an aliphatic acyl group, a nitro group or a nitrile group), R1 represents a hydrogen atom or a protective group of carboxylic acid, R2, R4 and R5 are the same or different and each represents a hydrogen atom, an aliphatic or aromatic acyl group; R3 represents an acetyl group, a glycolyl group or a trifluoroacetyl group; useful as reagent for detecting influenza virus A.Type: GrantFiled: December 23, 1998Date of Patent: March 20, 2001Assignee: Daikin Industries, Ltd.Inventors: Takao Iida, Yutaka Ohira
-
Patent number: 6190921Abstract: The invention deals with the use of a reactive compound in immunological analyses. The compound is ouabain or its analog to which another compound, labeled by radioiodine or by a fluorogen, is coupled. The invention covers also the method to measure ouabain or its analog in plasma to diagnose cardiovascular and endocrine diseases and other harmful conditions.Type: GrantFiled: January 20, 1999Date of Patent: February 20, 2001Inventors: Pekka Juhani Leppäluoto, Lauri Erkki Olli Vakkuri, Olli Jaakko Vuolteenaho
-
Patent number: 6187583Abstract: A vessel for conducting blood cell agglutination assays is disclosed. A barrier retains reactants in an upper chamber during incubation, then, in response to a force, permits reagents to enter a lower chamber containing a matrix for separating agglutination.Type: GrantFiled: May 28, 1998Date of Patent: February 13, 2001Inventors: Walter Milchanoski, Milan Jorik, Kathleen J. Reis, Diane E. Bechtold, Linda Davis, Thomas M. Setcavage
-
Patent number: 6184043Abstract: The invention relates to a method for detecting specific target-cells in a simple and time saving way, using paramagnetic particles, antibodies recognizing the Fc portions of target-cell associating antibodies and target-cell associating antibodies directed to specific antigen determinants in the target-cell membranes. Incubation of the cell suspension with a mild detergent and/or second set of antibodies or antibody fragments, prelabeled or not with fluorescent agents, metallocolloids, radioisotopes, biotincomplexes or certain enzymes allowing visualization, with dramatically increase the specificity of the method. The method can further be used for isolation of the target-cells by magnetic field application and kit for performing the method according to the invention is described.Type: GrantFiled: June 24, 1997Date of Patent: February 6, 2001Inventors: Øystein Fodstad, Gunnar Kvalheim